# Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects

> **NCT02227030** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 71 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIIB 722 CL solution
- **DRUG:** BIIB 722 CL tablet
- **DRUG:** Placebo solution
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT02227030
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2000-09
- **Final completion:** —
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227030, "Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02227030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*